InSite Vision anticipates initiating a Phase 1/2 clinical trial in 2011 to evaluate the safety and efficacy of ISV-101 when administered twice daily to patients suffering from dry eye disease. The five-arm trial design will include three ISV-101 dose concentrations and comparisons against DuraSite and non-DuraSite (placebo) vehicles. Data from the Phase 1/2 study are expected to provide guidance on the ideal dose for ISV-101 and the design of a Phase 3 clinical program.
See this Amp at http://bit.ly/g28SKY
No comments:
Post a Comment